SDX-101, the R-Enantiomer of Etodolac, Induces Cytotoxicity, Overcomes Drug

Resistance, and Enhances the Activity of Dexamethasone in Multiple Myeloma
, as well as high-dose chemotherapy combined with stem cell transplantation [3] [4] [5] , due to ,at least in part, both intrinsic and acquired drug resistance [6] [7] [8] . insulin-like growth factor-1 (IGF-1)) [9] [10] [11] [12] . Rationally-designed treatments targeting the BM microenvironment, as well as the MM cell, can overcome drug resistance in both preclinical and early clinical studies [13] [14] [15] [16] .
Etodolac (1,8-diethyl-1,3,4,9-tetrahydropyrano-[3,4-b] indole-1-acetic acid) is a non-steroidal anti-inflammatory drug (NSAID), that inhibits both cycloxygenase (COX)-1 and -2, and is approved for treatment of degenerative joint disease and rheumatoid arthritis 17, 18 . Etodolac exists as a racemic mixture of the R-and S-enantiomers, and unlike all other chiral NSAIDs, the two enantiomers of etodolac are not metabolically interconvertible. The R-Etodolac isoform (SDX-101) lacks significant COX inhibitory activity, and thereby has a more favorable safety profile than the racemic etodolac due to lack of COX-dependent side effects, such as gastrointestinal toxicity. Yasui H et al.
-6 -dye exclusion using light microscopy, as previously described 26 .
Primary MM Cells and BMSCs from MM Patients
Tumor cells (>90% CD138+) were purified from MM patient BM using the RosetteSep negative selection system (StemCell Technologies, Vancouver, British Columbia, Canada), as described previously 27 . BM mononuclear cells separated by
Ficoll-Hypaque (Pharmacia, Piscataway, NJ) were cultured in DMEM (Sigma Chemical, St Louis, MO) supplemented with 20 % heat-inactivated feral bovine serum, 2 µM L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin for 3-6 weeks to generate BM stromal cells (SCs) 28 . Approval for these studies was obtained from the Dana-Farber Cancer Institute Institutional Review Board. Informed consent was obtained from all patients in accordance with the Declaration of Helsinki protocol.
Growth inhibition assay
The growth inhibitory effect of R-etodolac or Dex on growth of MM cell lines, peripheral blood mononuclear cells (PBMCs), and BMSCs was assessed by measuring
International Inc., Temecula, CA) dye absorbance, as previously described 27 .
Immunoblotting
MM cells were cultured with R-etodolac, in the presence or absence of caspase inhibitors; harvested; washed; and lysed using lysis buffer: 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 10 mM sodium pyrophosphate, 5 mM EDTA, 1 mM EGTA, 2 mM Na 3 VO 4 , 5 mM NaF, 1 mM PMSF, 5 µg/ml leupeptin, and 5 µg/ml aprotinin, as only.
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Cell cycle profiling
MM.1S cells were treated with either R-etodolac or DMSO control prior to culture for 24
h. Cell cycle profiling was assessed by flow cytometry, as in prior studies 27 .
Effect of R-etodolac on MM cell growth in the BM
To 
Statistical analysis
Statistical significance of differences observed in R-etodolac-treated compared with control cultures was determined using a Student t test. The minimal level of significance was p < 0.01.
only.
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Isobologram analysis
The interaction between R-etodolac and Dex was analyzed using CalcuSyn software program (Biosoft, Ferguson,MO) to determine whether the combination was additive or synergistic, as described previously 30 31 . This program is based upon the Chou-Talalay method, which calculates a combination index (CI). Analysis is performed based on the 
R-etodolac induces down-regulation of Cyclin D1 expression
We and others have reported that expression of cyclin D1 is important for MM cell growth and prognosis 12, 35 . Since recent reports show that R-etodolac downregulates cyclin D1 expression and induces growth inhibition in CLL 19 and prostate cancer 20 , we next investigated whether R-etodolac down-regulates cyclin D1 in MM cells. In U266 cells, which are less sensitive to R-etodolac compared to other MM cells ( Figure 1A ), 1 mM R-etodolac induces growth inhibition but only minimal cell death ( Figure 3A ).
Immunoblotting shows that 1 mM R-etodolac significantly down-regulates cyclin D1 at 4h ( Figure 3B ) without significant change of cell cycle profile. Sub-G1 cells gradually increase to 20.9% of total at 36h ( Figure 3C ). These data suggest that R-etodolac down-regulates expression of cyclin D1 in MM cells and results in accumulation in an apoptotic population by cell cycle analysis 36 .
R-etodolac synergistically enhances dexamethasone cytotoxicity against MM cells.
As we have previously shown that novel chemotherapeutic agents can augment cytotoxicity of dexamethasone (Dex) 27, 29, 34, 37 , we further examined whether R-etodolac only.
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- 11 - To determine whether the combination therapy of R-etodolac with Dex has additive or synergistic cytotoxicity, we analyzed the interaction between Dex and R-etodolac by isobologram analysis using CalcuSyn software program 30 . Based upon the Chou-Talalay method, to calculate combination indices (CI), we generated dose effect curves for varying concentrations of Dex and R-etodolac ( Figure 4C ) 31 . At doses ranging from 0.25-2 µM of Dex combined with 75-600 µM of R-etodolac, CI ranged from 0 to 0.035, suggesting that this combination is strongly synergistic ( Figure 4D ). Figure 6B ). These results demonstrate that R-etodolac also has activity against refractory patient MM cells at clinically achievable plasma concentrations, as illustrated in previously reported studies in CLL patients 22 .
Subtoxic doses of R-etodolac induce upregulation of
R-etodolac overcomes the stimulatory effects of IL-6 and IGF-1
Since we and others have demonstrated that IL- 
R-etodolac inhibits MM cell growth triggered by tumor cell binding to BMSCs.
Since we previously showed that the BM microenvironment confers growth stimulating and drug resistance effects in MM cells 23, 28, [57] [58] [59] , we next studied the antagonistic effect of R-etodolac on paracrine MM cell growth in the BM milieu. We first examined the direct cytotoxicity of R-etodolac on patient BMSCs using MTT assay; 
Discussion
Although MM is incurable with conventional and high dose therapies, novel rationally-based treatment strategies both directly targeting MM cells as well as the BM microenvironment offer great promise to improve patient outcome since these approaches have the potential to overcome drug resistance as illustrated in both preclinical and clinical studies 13, 16 . In this report, we demonstrate that R-etodolac Recently, attention has been focused on the anti-proliferative activity of non-steroidal anti-inflammatory drugs (NSAIDs) and their potential utility as chemopreventive and anti-tumor agents 60 61 . To date, however, the mechanisms underlying the effects of these drugs on cancer cells are undefined. Although inhibition of COX with subsequent decrease in prostaglandin production may explain part of the anti-tumor activity of certain NSAIDs, some of these drugs exert anti-inflammatory and anti-tumor activity in COX-independent manners 62, 63 . For example, NSAIDs might inhibit nuclear factor-kappa B (NF-κB) signaling [64] [65] [66] [67] [68] 20, 21 , and MM supports the hypothesis that COX-independent mechanisms may be important in the anti-tumor activity of other NSAIDs.
As is true in thalidomide/IMiDs 37 only.
